Description

Diagnostic Hybrids, Inc. (DHI) is now recognized as the World’s Largest Cell Culture Provider serving the clinical virology market. DHI develops, manufactures, sells and distributes innovative tissue cell cultures, diagnostic kits and biochemical reagents to over 500 customers in the U.S., Canada, Europe, Australia and Japan. DHI’s products are developed and cleared for marketing by the U.S. Food & Drug Administration (FDA) and the Company expects to receive certification within the context of the International Standards Organization (ISO) by the fourth quarter of 2003. Most DHI products are designed in kit or complete systems formats, i.e. self-contained with all of the disposable materials included for performing a clinical diagnostic test. The notion of one-stop shopping is evident from the depth of our product offerings – we provide the swab to obtain the specimen from the patient, the transport medium that the swab must be placed in to insure the virus arrives in the laboratory in a “living” condition, the cells that the viruses need in order to replicate and manifest themselves in the laboratory setting and the fluorescent, monoclonal antibodies that identify and confirm the presence of the particular virus in the specimen. DHI was the first in the world to gain FDA clearance of a genetically engineered cell for clinical diagnostic purposes. ELVIS® HSV signals the presence of herpes simplex virus (HSV) in a clinical specimen by turning blue, making the detection of this virus faster (overnight compared to 7 days) and easier (colorless cells turning blue). The patented ELVIS HSV kit is available exclusively from DHI, and is one of many examples where DHI is applying biotechnology to modify the functional characteristics of cells. This innovative process leads to cells able to provide even greater benefits and advantages to clinical laboratory technologists around the world while maintaining a focus on cost-effective management of today’s diagnostic healthcare dollars. DHI also provides genetically modified cells useful for the detection of auto-antibodies that cause a hyperthyroid condition know as Graves' Disease. This disease is characterized by the presence of antibodies that the patient makes against his or her own thyroid. Having a 1% prevalence in the general population, Graves’ Disease is a common autoimmune disease which affects females about 10 times more frequently than males. DHI provides cells and reagents that are genetically engineered to produce luciferase, the enzyme in firefly tails that causes the production of light. Whenever a patient's serum containing minimum levels of Graves' antibodies is added to these cells, they emit light whenever a detection buffer is added to them. DHI's objective is to continually provide the healthcare profession with the very latest technology and tools to make the identification of viral and endocrine diseases faster, more accurate and in the most cost effective manner.

Technological Institute Profile

Terry Marovich Manager, HR and Corporate Communications Phone:(740) 593-1784 Alt. Phone: 1-800-344-5847 Fax: (740) 593-0980 Email: marovich@dhiusa.com Geoffrey Morgan Vice President/CFO Phone: (740) 593-1784 Alt. Phone: 1-800-344-5847 Fax:(740) 593-0980 Email: morgan@dhiusa.com...